Valirx (VAL)

 

VAL Share PerformanceMore

52 week high11.4900 04/10/16
52 week low1.8700 27/06/17
52 week change -5.0550 (-69.72%)
4 week volume15,274,979 28/06/17

Media for (VAL)

Presenter: Suzanne Dilly
15/06/2017
Presenter: Dr Satu Vainikka
08/05/2017

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Formation of & Appointments to an Advisory Board

RNS Number: 8054I ValiRx PLC 22 June 2017 ValiRx Plc ("ValiRx" or the "Company") FORMATION OF & APPOINTMENTS TO AN ADVISORY BOARD London, UK ., 22 June 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to announce the formation of an Advisory Board ("AB") and that the following individuals have agre...

ValiSeek Development Update - Recruitment Closes

RNS Number: 1252I ValiRx PLC 15 June 2017 ValiRx Plc ("ValiRx" or "the Company") ValiSeek Clinical Development Update Recruitment closes London, UK ., 15 June 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to provide an update on the clinical development of ValiSeek Limited ("ValiSeek"), the joint venture ("JV") between...

ValiRx - ValiSeek Clinical Development Update

ValiRx updates on Yorkville CLN Conversion

ValiRx has announced the conversion of the first tranche of the YA Global Master SPV Convertible Loan Facility (CLN). ...

Yorkville CLN Conversion

RNS Number: 8449G ValiRx PLC 01 June 2017 Va li R x P lc ("ValiRx" or "the Company" or "the Group") Yorkville CLN Conversion London, UK ., 1 June 2017: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation an...

Hardman Research:Developing novel cancer therapies

RNS Number: 6961G ValiRx PLC 31 May 2017 Hardman Research: Developing novel cancer therapies Developing novel cancer therapies: ValiRx is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company's two leading assets are in clinical trials:...

All resolutions passed at AGM of ValiRx

ValiRx has announced that, at its Annual General Meeting held earlier today, all resolutions were passed. At 3:01pm: (LON:V...

Result of AGM

RNS Number: 5406G ValiRx PLC 30 May 2017 ValiRx Plc ("ValiRx" or the "Company") RESULT OF ANNUAL GENERAL MEETING London, UK ., 30 May 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed. For more information, ple...

Fundamental DataMore

EPS-8.54
Dividend yield0 %

Equity Research (VAL)

hardman & co
ValiRx plc
31/05/2017
ValiRx is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading...
edison investment research
ValiRx plc
20/01/2015
V22 is an enterprise that showcases the wealth of talent in contemporary art. It has built a broad portfolio of around 150 artworks of living artists from around the world, paying in a mix of cash...

Latest discussion posts More

  • Ghostly Voice

    Looks like he was right again. bet they miss him on the LSE board
    1-Jun-2017
    nanbodo01
  • Ghostly voice

    Says news on Thursday will he be right again?
    30-May-2017
    nanbodo01
  • Re: Observations on the 2016 Annual Report &...

    you have very interesting proposal for val, i wonder if u can contact me on advfn (same id) by sending a message i would like to invite you to join other LTH members who r on ...
    14-May-2017
    y dino

Users' HoldingsMore

Users who hold Valirx also hold..
ROCKHOPPER18%
RANGE RES.17%
LLOYDS GRP.17%
SOUND ENERGY17%
SAREUM16%

Codes & Symbols

ISINGB00BWWYSP41
SymbolsVAL, LSE:VAL, VAL.L, VAL:LN, LON:VAL, XLON:VAL